文献速递神经重症神经肿瘤

颅骨修补术的抗菌生物材料:系统综述

Antimicrobial Biomaterials for Cranioplasty: A Systematic Review.
PubMed 文献 · World Neurosurg · 2025-05-13

本系统综述评估抗菌改性颅骨修补移植物的感染风险,纳入20项研究(10项体外研究、10项临床研究共234例患者)。体外研究显示高局部抗生素浓度和减少细菌定植,临床研究报告合并并发症率2.99%,仅1项研究进行统计比较,感染率2.6% vs 7.8%(P=0.179),差异无统计学意义。

要点

  • 抗菌改性颅骨修补材料体外研究显示高局部抗生素浓度和双相释放曲线(早期突释后持续低水平洗脱)。
  • 10项临床研究共234例患者,合并并发症率为2.99%。
  • 仅1项研究进行历史数据统计比较,感染率2.6% vs 7.8%(P=0.179),差异无统计学意义。

核心结论

  • 抗菌改性颅骨修补材料临床前结果有前景,局部释放曲线良好且全身分布极少,早期临床经验提示可能降低感染率,但当前证据受样本量小和方法学偏倚限制。
  • 需要设计良好的比较试验和标准化报告来确定明确的临床疗效,并指导最佳材料-抗生素组合和递送方法。

研究设计与样本

  • 遵循注册方案,2名评审员独立检索和筛选描述抗菌改性颅骨修补移植物的研究。
  • 纳入标准包括评估改性颅骨修补植入物(如嵌入、涂层或添加至储库的抗生素或纳米颗粒)的体外、体内和临床研究。
  • 共纳入20项研究:10项体外研究(其中2项也报告了体内模型结果)和10项临床研究(n=234例患者)。

主要发现

  • 聚合物、陶瓷或水凝胶移植物浸渍或涂覆各种抗菌剂,最常见的是氨基糖苷类。
  • 体外研究一致显示高局部抗生素浓度和减少细菌定植,具有早期突释和持续低水平洗脱的双相释放曲线。
  • 在有限的体内研究中,全身药物水平保持低水平。
  • 临床研究报告合并并发症率为2.99%。
  • 仅1项研究尝试与历史数据进行统计比较,发现感染率2.6% vs 7.8%(P=0.179),差异无统计学意义。

局限性

  • 大多数研究缺乏适当的对照组和足够的检验效能。
  • 仅1项研究尝试与历史数据进行统计比较,感染率2.6% vs 7.8%(P=0.179),差异无统计学意义。
  • 当前证据受样本量小和方法学偏倚限制。
  • 需要设计良好的比较试验和标准化报告来确定明确的临床疗效,并指导最佳材料-抗生素组合和递送方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cranioplasty is a surgical procedure performed to reconstruct the calvarium, yet it carries a significant risk of infection and subsequent graft failure. Surgical asepsis, systemic antibiotic prophylaxis, and topical antiseptics may reduce this risk, but recent attention has focused on incorporating antimicrobial agents or properties directly onto or into the implant. This systematic review assesses the efficacy of antibacterial-modified cranioplasty grafts in reducing infection risk. METHODS: Following a registered protocol, 2 reviewers independently searched and screened for studies describing antibacterial-modified cranioplasty grafts. Inclusion criteria included in vitro, in vivo, and clinical studies evaluating altered cranioplasty implants (e.g., antibiotics or nanoparticles embedded, coated, or added to a reservoir). The primary outcome measures were suitable measures of infection, with additional outcomes including antibiotic release profile. RESULTS: Twenty studies met the inclusion criteria: 10 in vitro studies (2 also reporting results of in vivo models) and 10 clinical studies (n = 234 patients). Polymeric, ceramic, or hydrogel grafts were impregnated or coated with various antimicrobial agents, most commonly aminoglycosides. In vitro studies consistently demonstrated high local antibiotic concentrations and reduced bacterial colonization, with a biphasic release profile characterized by an early burst and sustained low-level elution. In limited in vivo studies, systemic drug levels remained low. Clinical studies reported a combined complication rate of 2.99%. While this may indicate an improvement over historical complication rates, most studies lacked appropriate comparators and sufficient power: only 1 study attempted a statistical comparison with historical data, finding a nonsignificant reduction in infection (2.6% vs. 7.8%; P = 0.179). CONCLUSIONS: Antimicrobial modifications to cranioplasty materials show promising preclinical results, with favorable local release profiles and minimal systemic distribution. Early clinical experiences suggest a possible reduction in infection rates, but the current evidence is limited by small sample sizes and methodological biases. Well-designed comparative trials with standardized reporting are necessary to establish definitive clinical efficacy and to guide optimal material-antibiotic combinations and delivery methods.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Chaudri T, Belli A, Davies DJ, et al. Antimicrobial Biomaterials for Cranioplasty: A Systematic Review. World Neurosurg. 2025. PMID: 40373969. doi:10.1016/j.wneu.2025.124075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。